Search Results - Katharine E. Pestell

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    Identification of a Potent and Selective Pharmacophore for Cdc25 Dual Specificity Phosphatase Inhibitors

    Identification of a Potent and Selective Pharmacophore for Cdc25 Dual Specificity Phosphatase Inhibitors by Lazo, John S, Nemoto, Kaoru, Pestell, Katharine E, Cooley, Kathleen, Southwick, Eileen C, Mitchell, Douglas A, Furey, William, Gussio, Rick, Zaharevitz, Daniel W, Joo, Beomjun, Wipf, Peter

    Published in Molecular pharmacology
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Effect of p53 Status on Sensitivity to Platinum Complexes in a Human Ovarian Cancer Cell Line

    Effect of p53 Status on Sensitivity to Platinum Complexes in a Human Ovarian Cancer Cell Line by Pestell, K E, Hobbs, S M, Titley, J C, Kelland, L R, Walton, M I

    Published in Molecular pharmacology
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    Paul Workman on the challenges of cancer drug development

    Paul Workman on the challenges of cancer drug development by Pestell, Katharine E.

    Published in Drug discovery today
    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  4. 4
    The antisignaling agent SC-alpha alpha delta 9, 4-(benzyl-(2-[(2,5-diphenyloxazole-4-carbonyl)amino]ethyl)carbamoyl)- 2-decanoylaminobutyric acid, is a structurally unique phospholipid analogue with phospholipase C inhibitory activity

    The antisignaling agent SC-alpha alpha delta 9, 4-(benzyl-(2-[(2,5-diphenyloxazole-4-carbonyl)amino]ethyl)carbamoyl)- 2-decanoylaminobutyric acid, is a structurally unique phosphol... by Vogt, Andreas, Pestell, Katharine E, Day, Billy W, Lazo, John S, Wipf, Peter

    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Characterisation of the P53 status, BCL‐2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines

    Characterisation of the P53 status, BCL‐2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines by Pestell, Katharine E., Medlow, Clare J., Titley, Jenny C., Kelland, Lloyd R., Walton, Michael I.

    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    The Antisignaling Agent SC-ααδ9, 4-(Benzyl-(2-[(2,5-diphenyloxazole- 4-carbonyl)amino]ethyl)carbamoyl)- 2-decanoylaminobutyric Acid, Is a Structurally Unique Phospholipid Analogue with Phospholipase C Inhibitory Activity 1 This work was supported by Institutional Research Grant 60-002-40-IRG from the American Cancer Society, The Fiske Drug Discovery Fund, and NIH Grants CA-78039 and 52995. 1

    The Antisignaling Agent SC-ααδ9, 4-(Benzyl-(2-[(2,5-diphenyloxazole- 4-carbonyl)amino]ethyl)carbamoyl)- 2-decanoylaminobutyric Acid, Is a Structurally Unique Phospholipid Analogue... by Andreas Vogt, Katharine E. Pestell, Billy W. Day, John S. Lazo, Peter Wipf

    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Characterisation of theP53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines

    Characterisation of theP53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines by Pestell, Katharine E., Medlow, Clare J., Titley, Jenny C., Kelland, Lloyd R., Walton, Michael I.

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:

Search Tools: